Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Dow
McKinsey
AstraZeneca
McKesson

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR CRIZOTINIB


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Crizotinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00828919 ↗ Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials Active, not recruiting Pfizer N/A 2003-03-07 To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical benefit in a closing axitinib trial
NCT00939770 ↗ Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed National Cancer Institute (NCI) Phase 1/Phase 2 2009-09-21 This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗ Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed Pfizer Phase 1/Phase 2 2009-09-21 This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT00939770 ↗ Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed Children's Oncology Group Phase 1/Phase 2 2009-09-21 This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement or does not respond to treatment. Crizotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. (Phase 1 completed 2/15/13)
NCT01082380 ↗ Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers Completed Pfizer Phase 1 2010-03-01 The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066 in humans.
NCT01121588 ↗ An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) Active, not recruiting Pfizer Phase 1 2011-03-22 This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
NCT01125904 ↗ A Study To Investigate The Taste Of Crizotinib Liquid In Trained Healthy Adult Volunteers Completed Pfizer Phase 1 2010-06-01 An oral-liquid, pediatric form of crizotinib designed for use by pediatric patients is being tested for its' palatability in adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Crizotinib

Condition Name

Condition Name for Crizotinib
Intervention Trials
Non-small Cell Lung Cancer 29
Healthy 10
Carcinoma, Non-Small-Cell Lung 9
Lung Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Crizotinib
Intervention Trials
Carcinoma, Non-Small-Cell Lung 70
Lung Neoplasms 60
Neoplasms 21
Lymphoma 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Crizotinib

Trials by Country

Trials by Country for Crizotinib
Location Trials
United States 936
China 156
Italy 111
Japan 73
Spain 72
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Crizotinib
Location Trials
California 41
Texas 39
New York 36
Massachusetts 35
Florida 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Crizotinib

Clinical Trial Phase

Clinical Trial Phase for Crizotinib
Clinical Trial Phase Trials
Phase 4 4
Phase 3 18
Phase 2/Phase 3 1
[disabled in preview] 120
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Crizotinib
Clinical Trial Phase Trials
Completed 47
Recruiting 45
Active, not recruiting 24
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Crizotinib

Sponsor Name

Sponsor Name for Crizotinib
Sponsor Trials
Pfizer 56
National Cancer Institute (NCI) 17
Hoffmann-La Roche 10
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Crizotinib
Sponsor Trials
Other 160
Industry 143
NIH 17
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Medtronic
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.